The effect of vitamin C on procalcitonin biomarker in community-acquired pneumonia.

Q2 Medicine

Clinical and Molecular Allergy Pub Date : 2021-03-03 DOI:10.1186/s12948-021-00140-1

Mahsa Nikzad, Hamid Reza Banafshe, Mansooreh Momen-Heravi, Hamed Haddad Kashani, Maryam Shiehmorteza

{"title":"The effect of vitamin C on procalcitonin biomarker in community-acquired pneumonia.","authors":"Mahsa Nikzad, Hamid Reza Banafshe, Mansooreh Momen-Heravi, Hamed Haddad Kashani, Maryam Shiehmorteza","doi":"10.1186/s12948-021-00140-1","DOIUrl":null,"url":null,"abstract":"Introduction: Community acquired pneumonia (CAP) is a prevalent low respiratory infection. Diagnosis is based on clinical symptoms, radiologic evidence and culture. Biomarkers such as IL6, CRP and procalcitonin are helpful in diagnosis. Procalcitonin is a soluble biomarker in serum that increase in systemic inflammation and bacterial infections. People with normal procalcitonin have low risk to infect pneumonia. Patient with CAP have more oxidative stress than normal people. Studies show that receiving vitamin C can reduce incidence of pneumonia. The present study was designed to evaluate the effect of vitamin C supplement on procalcitonin biomarker in patient with CAP.Methods: Patients with CAP who passed inclusion and exclusion criteria after obtaining informed consent, were assigned randomly in two groups of drug and placebo. The drug group received vitamin C (1000 mg/d) daily and medications that physician prescribed for treating CAP for 10 days and placebo group received placebo and medications that physician prescribed. The serum level of procalcitonin was measured at the beginning of the study and after 10 days of intervention.Results: 35 patients finished the study. Serum level of procalcitonin on the first and tenth day did not show any significant difference between drug and placebo groups.Conclusions: To clarify the relationship between the effects of vitamin C on procalcitonin in CAP, a larger sample size is required.","PeriodicalId":38753,"journal":{"name":"Clinical and Molecular Allergy","volume":"19 1","pages":"1"},"PeriodicalIF":0.0000,"publicationDate":"2021-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12948-021-00140-1","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Molecular Allergy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s12948-021-00140-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 4

Abstract

Introduction: Community acquired pneumonia (CAP) is a prevalent low respiratory infection. Diagnosis is based on clinical symptoms, radiologic evidence and culture. Biomarkers such as IL6, CRP and procalcitonin are helpful in diagnosis. Procalcitonin is a soluble biomarker in serum that increase in systemic inflammation and bacterial infections. People with normal procalcitonin have low risk to infect pneumonia. Patient with CAP have more oxidative stress than normal people. Studies show that receiving vitamin C can reduce incidence of pneumonia. The present study was designed to evaluate the effect of vitamin C supplement on procalcitonin biomarker in patient with CAP.

Methods: Patients with CAP who passed inclusion and exclusion criteria after obtaining informed consent, were assigned randomly in two groups of drug and placebo. The drug group received vitamin C (1000 mg/d) daily and medications that physician prescribed for treating CAP for 10 days and placebo group received placebo and medications that physician prescribed. The serum level of procalcitonin was measured at the beginning of the study and after 10 days of intervention.

Results: 35 patients finished the study. Serum level of procalcitonin on the first and tenth day did not show any significant difference between drug and placebo groups.

Conclusions: To clarify the relationship between the effects of vitamin C on procalcitonin in CAP, a larger sample size is required.

Abstract Image

查看原文本刊更多论文

维生素C对社区获得性肺炎降钙素原生物标志物的影响。

社区获得性肺炎(CAP)是一种常见的下呼吸道感染。诊断依据临床症状、放射学证据和培养。生物标志物如il - 6、CRP和降钙素原对诊断有帮助。降钙素原是血清中的可溶性生物标志物，可增加全身性炎症和细菌感染。降钙素原正常的人感染肺炎的风险较低。CAP患者的氧化应激水平高于正常人。研究表明，服用维生素C可以减少肺炎的发病率。本研究旨在评价维生素C补充剂对CAP患者降钙素原生物标志物的影响。方法:经知情同意，通过纳入和排除标准的CAP患者，随机分为药物组和安慰剂组。药物组每天服用维生素C (1000 mg/d)并服用医生处方治疗CAP的药物，持续10天，安慰剂组服用安慰剂并服用医生处方药物。在研究开始时和干预10天后测量血清降钙素原水平。结果:35例患者完成研究。药物组和安慰剂组第1天和第10天血清降钙素原水平无显著差异。结论:为了阐明维生素C对CAP降钙素原的影响之间的关系，需要更大的样本量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Molecular Allergy Medicine-Immunology and Allergy

CiteScore

8.20

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Clinical and Molecular Allergy is an open access, peer-reviewed, online journal that publishes research on human allergic and immunodeficient disease (immune deficiency not related to HIV infection/AIDS). The scope of the journal encompasses all aspects of the clinical, genetic, molecular and inflammatory aspects of allergic-respiratory (Type 1 hypersensitivity) and non-AIDS immunodeficiency disorders. However, studies of allergic/hypersensitive aspects of HIV infection/AIDS or drug desensitization protocols in AIDS are acceptable. At the basic science level, this includes original work and reviews on the genetic and molecular mechanisms underlying the inflammatory response.